CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Estadual de Campinas (UNICAMP). Instituto de Biologia (IB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Graduated in Pharmacy from the Federal University of Rio de Janeiro (1986), Master in Biological Sciences (Microbiology) from the Federal University of Rio de Janeiro (1989), PhD in Biological Sciences (Microbiology) from the Federal University of Rio de Janeiro (1992) / University of Illinois at Urbana Champaign (United States), Postdoctoral and Habilitation at the State University of Campinas. She is currently Associate Professor in Biochemistry at the State University of Campinas. At the Laboratory of Antioxidant Defenses of Trypanosoma cruzi (LABDAT), she coordinates projects to study the antioxidant mechanisms and mitochondrial bioenergetics of T. cruzi isolates from patients with different clinical forms of Chagas disease and the investigation of trypanocidal compounds. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Chagas disease (CD) has different clinical forms that vary among individuals and geographic regions. CD geographic heterogeneity suggests that the genetic variability of the host, the parasite, or of both are important for the development of the distinct clinical forms of the disease. Besides that, the heterogeneity among Trypanosoma cruzi strains has been the Achile's heel for the develo…
Among the proteins of the Trypanosoma cruzi antioxidant system, cytosolic and mitochondrial tryparedoxin peroxidase (TcMPx) that have an important role in parasite's virulence and viability. The cytosolic antioxidant system has been elucidated, but how the mitochondrial system dependent on TcMPx works is still unclear. Bioinformatics analysis, immulocalization and bioenergetics experiment…
(Only some records are available in English at this moment)
Trypanosoma cruzi is the etiological agent of Chagas disease (CD). Currently, treatment is limited to a single drug that is not effective in the chronic phase and leads to serious side effects, making the search for a new drug a priority. The group of Prof. Camilla Abbehausen, from IQ-UNICAMP, has been studying, together with Prof. Danilo Miguel, from IB-UNICAMP, the effect of metallodrug…
Chagas disease (CD) has different clinical manifestations (indeterminate, cardiac, cardio-digestive and digestive) that vary among individuals and geographic regions. CD heterogeneity suggests that the genetic variation of the host and/or the parasite is important for the establishment of the distinct clinical forms. Analyzing eight Trypanosoma cruzi isolates from patients bearing distinc…
Chagas disease (CD) whose etiologic agent is Trypanosoma cruzi has four clinical forms (cardiac, digestive, cardio-digestive and indeterminate). It is estimated that approximated 8 million people are infected with DC in Latin America. Unfortunately, there isn't an effective treatment for the disease. The geographic heterogeneity of DC suggests that a genetic variation in the host or in th…
Chagas disease (CD) has distincts clinical manifestations, which varies among individuals and geographical regions. The geographical heterogenity of CD suggests that the genetic variation of the host, the parasite, or both, are relevant for the establishment of the clinical form of the disease. The diversity that exists among Trypanosoma cruzi strains has been the Aquiles's heel for the d…
(Only some records are available in English at this moment)
The requirement for new treatments targeting Trypanosoma cruzi, the causative agent of Chagas disease, is urgently needed. One potential Achilles? heel is the systems it employs to detoxify reactive oxygen species. For peroxide metabolism, a series of enzymatic pathways dependent on the trypanosome specific thiol trypanothione have been reported. However, although a mitochondrial antioxid…
| 9 / 7 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 14 / 8 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 25 / 17 | All research grants and scholarships |
| Associated processes | |